This company develops novel therapeutics by integrating covalent chemistry with artificial intelligence platforms. They build intelligent systems that learn from experimental data to design new medicines. The core focus is creating targeted treatments for diseases driven by specific proteins previously considered undruggable.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many disease‑driving proteins lack suitable binding pockets for conventional small‑molecule drugs, leaving patients without targeted therapeutic options despite clear biological relevance.
Solution
Expedition Medicines combines covalent chemistry with advanced artificial‑intelligence platforms to design small molecules that form irreversible bonds with protein surfaces previously deemed undruggable. Their generative chemistry engine learns from a continuously expanding, proteome‑wide dataset of covalent reaction outcomes, enabling rapid hypothesis testing and candidate optimization. By integrating quantum‑chemical electron‑density modeling, the system predicts the reactivity and selectivity of covalent warheads at atomic resolution. The platform automates synthesis route planning and provides cloud‑hosted analytics, allowing researchers to iterate from target identification to preclinical candidate within a unified workflow. This approach expands the druggable proteome and creates new treatment possibilities for patients whose diseases are driven by known but inaccessible proteins.
Target Audience
Primary customers are pharmaceutical and biotechnology R&D organizations seeking to develop first‑in‑class therapies for targets that are currently considered undruggable, as well as academic drug‑discovery groups requiring advanced covalent design capabilities.
Features
- AI‑driven generative design engine that proposes covalent ligands tailored to any protein surface.
- High‑throughput data generation platform measuring covalent bond formation across the entire proteome with atomic precision.
- Quantum chemistry module that computes electron‑cloud interactions to predict warhead reactivity and off‑target risk.
- Integrated chemoproteomics pipeline linking experimental covalent binding data to AI model training.
- Automated synthesis planning and retrosynthetic route optimization for rapid candidate production.
- Cloud‑based analytics dashboard delivering real‑time potency, selectivity, and pharmacokinetic predictions.
- Proprietary database of covalent reaction outcomes enabling continual model refinement and knowledge transfer across projects.